HUE059774T2 - Kognitív és hangulati szimptómák kezelése neurodegeneratív és neuropszichiátriai betegségekben ALFA5-öt tartalmazó GABAA receptoragonistákkal - Google Patents
Kognitív és hangulati szimptómák kezelése neurodegeneratív és neuropszichiátriai betegségekben ALFA5-öt tartalmazó GABAA receptoragonistákkalInfo
- Publication number
- HUE059774T2 HUE059774T2 HUE17767701A HUE17767701A HUE059774T2 HU E059774 T2 HUE059774 T2 HU E059774T2 HU E17767701 A HUE17767701 A HU E17767701A HU E17767701 A HUE17767701 A HU E17767701A HU E059774 T2 HUE059774 T2 HU E059774T2
- Authority
- HU
- Hungary
- Prior art keywords
- alfa5
- neurodegenerative
- cognitive
- treatment
- receptor agonists
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title 1
- 108091008681 GABAA receptors Proteins 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000036651 mood Effects 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310409P | 2016-03-18 | 2016-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE059774T2 true HUE059774T2 (hu) | 2023-01-28 |
Family
ID=59851645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17767701A HUE059774T2 (hu) | 2016-03-18 | 2017-03-20 | Kognitív és hangulati szimptómák kezelése neurodegeneratív és neuropszichiátriai betegségekben ALFA5-öt tartalmazó GABAA receptoragonistákkal |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10906909B2 (https=) |
| EP (2) | EP3439665B1 (https=) |
| JP (2) | JP7023876B2 (https=) |
| AU (2) | AU2017235665B2 (https=) |
| CA (1) | CA3016491A1 (https=) |
| CY (1) | CY1125576T1 (https=) |
| DK (1) | DK3439665T3 (https=) |
| ES (1) | ES2926918T3 (https=) |
| HR (1) | HRP20221098T1 (https=) |
| HU (1) | HUE059774T2 (https=) |
| LT (1) | LT3439665T (https=) |
| PL (1) | PL3439665T3 (https=) |
| PT (1) | PT3439665T (https=) |
| RS (1) | RS63674B1 (https=) |
| SI (1) | SI3439665T1 (https=) |
| SM (1) | SMT202200372T1 (https=) |
| WO (1) | WO2017161370A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7013446B2 (ja) | 2016-08-16 | 2022-02-15 | ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド | Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法 |
| US20220105106A1 (en) * | 2019-02-13 | 2022-04-07 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| SG11202109526PA (en) * | 2019-03-18 | 2021-10-28 | Neurocycle Therapeutics Inc | Use of gabaa receptor modulators for treatment of pain |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| US20240374612A1 (en) * | 2021-09-08 | 2024-11-14 | Uwm Research Foundation, Inc. | Imidazobenzodiazepines for treatment of cognitive and mood symptoms |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| AU2022359461A1 (en) * | 2021-10-07 | 2024-05-02 | Pantherics Incorporated | Methods and compounds for treating inflammation |
| WO2024077061A2 (en) * | 2022-10-04 | 2024-04-11 | Uwm Research Foundation, Inc. | Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation |
| IT202400001089A1 (it) * | 2024-01-22 | 2025-07-22 | Fondazione St Italiano Tecnologia | Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA755418B (en) * | 1974-09-11 | 1977-06-29 | Hoffmann La Roche | Diazepine derivatives |
| US4226768A (en) | 1979-05-29 | 1980-10-07 | Hoffmann-La Roche Inc. | Process for the preparation of imidazobenzodiazepines |
| US20030176456A1 (en) | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| USRE47475E1 (en) | 2002-03-28 | 2019-07-02 | Wisys Technology Foundation, Inc. | Selective agents for pain suppression |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| CA2570185A1 (en) | 2004-06-30 | 2006-01-12 | Wisys Technology Foundation Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| US20100130479A1 (en) | 2005-05-16 | 2010-05-27 | Cook James M | Gabaergic Agents to Treat Memory Deficits |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| WO2007042544A2 (en) | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Imidazole derivatives and their use for modulating the gabaa receptor complex |
| DE102006023554A1 (de) | 2006-05-19 | 2007-11-22 | Zf Friedrichshafen Ag | Ermittlung der Drehzahl einer Getriebewelle |
| US8119629B2 (en) | 2007-10-03 | 2012-02-21 | Bristol-Meyers Squibb Company | Carboxamide GABAA α2 modulators |
| EP2364571B1 (en) | 2008-10-02 | 2012-08-22 | Telefonaktiebolaget L M Ericsson (PUBL) | Wireless communication system and method for assigning a channel in said wireless communication system |
| US20100261711A1 (en) | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
| US9006233B2 (en) | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| CA2979701C (en) | 2015-03-20 | 2023-01-03 | Uwm Research Foundation, Inc. | Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands |
-
2017
- 2017-03-20 DK DK17767701.0T patent/DK3439665T3/da active
- 2017-03-20 PT PT177677010T patent/PT3439665T/pt unknown
- 2017-03-20 HR HRP20221098TT patent/HRP20221098T1/hr unknown
- 2017-03-20 CA CA3016491A patent/CA3016491A1/en active Pending
- 2017-03-20 RS RS20220892A patent/RS63674B1/sr unknown
- 2017-03-20 AU AU2017235665A patent/AU2017235665B2/en active Active
- 2017-03-20 WO PCT/US2017/023206 patent/WO2017161370A1/en not_active Ceased
- 2017-03-20 SI SI201731230T patent/SI3439665T1/sl unknown
- 2017-03-20 PL PL17767701.0T patent/PL3439665T3/pl unknown
- 2017-03-20 ES ES17767701T patent/ES2926918T3/es active Active
- 2017-03-20 US US16/086,053 patent/US10906909B2/en active Active
- 2017-03-20 JP JP2018568186A patent/JP7023876B2/ja active Active
- 2017-03-20 EP EP17767701.0A patent/EP3439665B1/en active Active
- 2017-03-20 EP EP22181243.1A patent/EP4129297A1/en active Pending
- 2017-03-20 SM SM20220372T patent/SMT202200372T1/it unknown
- 2017-03-20 LT LTEPPCT/US2017/023206T patent/LT3439665T/lt unknown
- 2017-03-20 HU HUE17767701A patent/HUE059774T2/hu unknown
-
2020
- 2020-12-15 US US17/122,745 patent/US11753412B2/en active Active
-
2022
- 2022-02-08 JP JP2022017827A patent/JP7515526B2/ja active Active
- 2022-09-27 CY CY20221100636T patent/CY1125576T1/el unknown
- 2022-11-23 AU AU2022275446A patent/AU2022275446B2/en active Active
-
2023
- 2023-08-02 US US18/363,933 patent/US12180216B2/en active Active
-
2024
- 2024-11-12 US US18/944,947 patent/US20250179080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3439665T (lt) | 2022-10-10 |
| PT3439665T (pt) | 2022-09-27 |
| US12180216B2 (en) | 2024-12-31 |
| HRP20221098T1 (hr) | 2022-11-25 |
| AU2017235665B2 (en) | 2022-12-08 |
| WO2017161370A1 (en) | 2017-09-21 |
| EP3439665A1 (en) | 2019-02-13 |
| DK3439665T3 (da) | 2022-09-26 |
| JP2019509340A (ja) | 2019-04-04 |
| AU2022275446B2 (en) | 2025-01-02 |
| RS63674B1 (sr) | 2022-11-30 |
| AU2022275446A1 (en) | 2023-01-05 |
| EP3439665A4 (en) | 2019-11-27 |
| JP2022065035A (ja) | 2022-04-26 |
| SMT202200372T1 (it) | 2022-11-18 |
| PL3439665T3 (pl) | 2023-01-16 |
| CA3016491A1 (en) | 2017-09-21 |
| SI3439665T1 (sl) | 2023-05-31 |
| US11753412B2 (en) | 2023-09-12 |
| EP4129297A1 (en) | 2023-02-08 |
| EP3439665B1 (en) | 2022-06-29 |
| US20210309662A1 (en) | 2021-10-07 |
| JP7515526B2 (ja) | 2024-07-12 |
| ES2926918T3 (es) | 2022-10-31 |
| CY1125576T1 (el) | 2026-02-25 |
| US10906909B2 (en) | 2021-02-02 |
| US20200181146A1 (en) | 2020-06-11 |
| US20240083905A1 (en) | 2024-03-14 |
| WO2017161370A8 (en) | 2018-09-27 |
| JP7023876B2 (ja) | 2022-02-22 |
| US20250179080A1 (en) | 2025-06-05 |
| AU2017235665A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE059774T2 (hu) | Kognitív és hangulati szimptómák kezelése neurodegeneratív és neuropszichiátriai betegségekben ALFA5-öt tartalmazó GABAA receptoragonistákkal | |
| IL255992B (en) | Methods of in vitro differentiation of midbrain dopamine (mda) neurons | |
| HUE058755T2 (hu) | Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei | |
| IL257065A (en) | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| DK3119881T3 (da) | Production of midbrain dopaminergic neurons and methods for the use thereof | |
| HUE061506T2 (hu) | Kolán származékok FXR és TGR5/GPBAR1 által közvetített betegségek kezelésében történõ alkalmazásra | |
| FR25C1031I2 (fr) | Traitement de maladies cholestatiques intrahepatiques | |
| HUE053968T2 (hu) | Triazinon vázzal és imidazo-pirazinon vázzal rendelkezõ PDE9 inhibitorok perifériás betegségek kezelésére | |
| HUE046397T2 (hu) | Artemizinin vegyületek és gefirin agonisták gyógyászati alkalmazása | |
| EP3503903A4 (en) | ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | |
| EP3432888A4 (en) | CANCER TREATMENT WITH TG02 | |
| EP3458454A4 (en) | Novel mitochondrial decouplers for the treatment of metabolic diseases and cancer | |
| EP3373962A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES | |
| HUE037663T2 (hu) | Kalcitonin mimetikumok betegségek és rendellenességek kezelésére | |
| EP3273955A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| HUE054093T2 (hu) | Anti-HtrA1 antitestek és azok alkalmazási eljárásai | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| EP3347492A4 (en) | METHOD FOR HISTOLOGICAL DIAGNOSIS AND TREATMENT OF ILLNESSES | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| HUE055974T2 (hu) | Tesofensine és metoprolol kombinációs készítmény | |
| EP3344258A4 (en) | TREATMENT OF AUTOIMMUNE DISEASES AND AUTO IGNITION DISEASES | |
| IL259486A (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
| HUE045025T2 (hu) | Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére | |
| EP3414015A4 (en) | CENTRIFUGE AND SYSTEM FOR A BODY FLUID SAMPLE |